The drug imatinib acts by the inhibition of:
**Core Concept**
Imatinib is a tyrosine kinase inhibitor used in the treatment of certain types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). The drug targets specific enzymes involved in the signaling pathways that promote cell growth and proliferation.
**Why the Correct Answer is Right**
Imatinib works by selectively inhibiting the activity of the BCR-ABL tyrosine kinase enzyme, which is a fusion protein resulting from the Philadelphia chromosome abnormality in CML cells. By blocking this enzyme, imatinib prevents the phosphorylation of downstream signaling molecules, thereby inhibiting cell proliferation and inducing apoptosis. Imatinib also inhibits other tyrosine kinases, such as c-KIT and PDGFR, which are involved in the pathogenesis of GISTs.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because imatinib does not primarily inhibit the activity of topoisomerase II, which is a target of anthracycline antibiotics.
**Option B:** This option is incorrect because imatinib does not primarily inhibit the activity of histone deacetylase, which is a target of certain antipsychotic and antimicrobial agents.
**Option C:** This option is incorrect because imatinib does not primarily inhibit the activity of thymidylate synthase, which is a target of fluoropyrimidine chemotherapy agents.
**Clinical Pearl / High-Yield Fact**
Imatinib is a classic example of a targeted therapy, which is designed to specifically inhibit the activity of a particular molecular target involved in the pathogenesis of a disease.
**Correct Answer: C. Inhibition of BCR-ABL tyrosine kinase.**